A Systematic Review on Long-Term Efficacy Outcome Measures in Crohn’s Disease Patients
Journal of Crohn's and Colitis · 2023
DOI: 10.1093/ecco-jcc/jjad037 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Journal of Crohn's and Colitis, 2023. Verfasst von Laura M Janssen und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Division of Gastroenterology and Hepatology, Maastricht University Medical Centre+, Maastricht, The Netherlands. Hauptthemen laut MEDLINE: Crohn Disease, Leukocyte L1 Antigen Complex. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background
The traditional long-term treatment goal of Crohn’s disease [CD] is maintenance of corticosteroid-free clinical remission. Additional treatment targets, such as biochemical, endoscopic and patient-reported remission, are advocated. The relapsing–remitting nature of CD provides a challenge to the timing of target assessment. Cross-sectional assessment at predetermined moments disregards the health state in between measurements. In this systematic review, we provide an overview of outcomes used to assess long-term efficacy in clinical trials in CD.
Methods
A systematic search of the PubMed and EMBASE databases was performed to identify clinical trials in luminal CD reporting on maintenance treatment [strategies] since 1995. Two independent reviewers selected eligible articles for full text retrieval, and assessed if long-term corticosteroid-free clinical, biochemical, endoscopic or patient-reported efficacy outcomes were used.
Results
The search resulted in 2452 hits and 82 articles were included. Clinical activity was used in 80 studies [98%] as the long-term efficacy outcome, and in 21 [26%] of these concomitant corticosteroid use was taken into account. C-reactive protein was used in 32 studies [41%], faecal calprotectin in 15 studies [18%], endoscopic activity in 34 studies [41%] and patient-reported outcome in 32 studies [39%]. In seven studies, clinical, biochemical, endoscopic activity and the patient’s perspective were measured. In most studies cross-sectional measures or multiple measurements over time were used.
Conclusion
In none of the published clinical trials in CD was sustained remission on all treatment targets reported. Cross-sectional outcomes at predetermined times were widely applied, leading to lack of information regarding sustained corticosteroid-free remission for this relapsing–remitting chronic disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine, Division of Gastroenterology and Hepatology, Maastricht University Medical Centre+, Maastricht, The Netherlands.
- School for Nutrition and Translational Research in Metabolism (NUTRIM), Maastricht University Medical Centre+, Maastricht, The Netherlands.
- Department of Gastroenterology, Geriatrics, Internal and Intensive Care Medicine (Co-MIK), Zuyderland Medical Centre, Heerlen-Sittard-Geleen, The Netherlands.
ORCID-Profile: Laura M Janssen, Rob H Creemers, Marie J Pierik
Zitieren
APA
Janssen, L. M., Creemers, R. H., van Bodegraven, A. A., & Pierik, M. J. (2023). A Systematic Review on Long-Term Efficacy Outcome Measures in Crohn’s Disease Patients. Journal of Crohn's and Colitis. https://doi.org/10.1093/ecco-jcc/jjad037
Vancouver
Janssen LM, Creemers RH, van Bodegraven AA, Pierik MJ. A Systematic Review on Long-Term Efficacy Outcome Measures in Crohn’s Disease Patients. Journal of Crohn's and Colitis. 2023. doi:10.1093/ecco-jcc/jjad037
BibTeX
@article{Janssen2023,
author = {Janssen, Laura M and Creemers, Rob H and van Bodegraven, Adriaan A and Pierik, Marie J},
title = {A Systematic Review on Long-Term Efficacy Outcome Measures in Crohn’s Disease Patients},
journal = {Journal of Crohn's and Colitis},
year = {2023},
doi = {10.1093/ecco-jcc/jjad037}
}
EUVIMED